A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease

Status:
Completed

Trial end date:
2013-02-18

Target enrollment:

Participant gender:

The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.

Phase 2

GlaxoSmithKline